Evidence map›Paper›PMID 40853543›Full record

SynthesisInfection2025

Infection of the acromioclavicular joint with Mycobacterium bovis following intravesical instillation of Bacillus Calmette-Guerin: a case-based review.

Maxime Bosse, Benjamin Lardinois, Julie Cadrobbi, Sandrine Van Eeckhoudt, Pauline Sambon, Gaëtan Opsomer, Jeremie Gras, Vanessa Mathys, Kim Laffineur

Abstract readSystematic ReviewCase Reports
PubMed Publisher
In one paragraph

Synthesis in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maxime BosseDepartment of Clinical Microbiology, Clinique Saint-Luc, Bouge, Belgium. maxime.bosse@slbo.be.ORCID https://orcid.org/0009-0005-6069-8118
Benjamin LardinoisDepartment of Clinical Microbiology, Clinique Saint-Luc, Bouge, Belgium.ORCID https://orcid.org/0000-0003-2671-1196
Julie CadrobbiDepartment of Clinical Microbiology, Clinique Saint-Luc, Bouge, Belgium.
Sandrine Van EeckhoudtDepartment of Internal Medicine, Clinique Saint-Luc, Bouge, Belgium.
Pauline SambonDepartment of Internal Medicine, Clinique Saint-Luc, Bouge, Belgium.
Gaëtan OpsomerDepartment of Orthopaedic Surgery, Clinique Saint-Luc, Bouge, Belgium.
Jeremie GrasInstitute of Pathology and Genetics, Gosselies, Belgium.ORCID https://orcid.org/0009-0007-2518-102X
Vanessa MathysBacterial Diseases Service, NRC Mycobacterium, Sciensano, Brussels, Belgium.ORCID https://orcid.org/0000-0001-5218-927X
Kim LaffineurDepartment of Clinical Microbiology, Clinique Saint-Luc, Bouge, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOsteoarticular infections caused by intravesical BCG are rare and poorly characterized. This study presents a case of acromioclavicular joint infection caused by Mycobacterium bovis BCG, alongside a systematic review aimed at improving our understanding of the infection's clinical features, diagnosis, treatment and outcomes.

methodsThis systematic review included all published cases of osteoarticular infections due to M. bovis BCG following intravesical BCG instillation, as identified through a PubMed search conducted up to 1 May 2025. The search used combinations of keywords related to 'BCG', 'bladder', and 'osteoarticular infection'. One additional case from our institution was added. Clinical, biological, radiological, treatment and outcome data were extracted and analyzed.

resultsWe reviewed 67 cases, classified as vertebral (n = 45), prosthetic joint (n = 18), and native joint (n = 4). The affected patients were predominantly men (98.5%), with a mean age of 74.1 ± 9.2 years. The median delay in months between the first instillation and the diagnosis was 23 [IQR 13.0-48.0]. Fever was uncommon (20.5%), while elevated C-reactive protein levels were frequent (80%). Imaging (CT/MRI) played a key role in diagnosis by showing images consistent with infection in all cases in which it was used. Treatment typically involved rifampicin and isoniazid for 12 months, alongside ethambutol for two months. Outcomes were favorable in 90.6% of cases, with one death attributed to the infection.

conclusionThough rare, M. bovis BCG osteoarticular infections should be considered in patients with unexplained joint symptoms following BCG therapy. Early diagnosis and appropriate therapy are essential for optimal management.

Indexed as

Acromioclavicular JointBCG VaccineMycobacterium bovisTuberculosis, OsteoarticularAdministration, IntravesicalAgedAged, 80 and overAntitubercular AgentsFemaleHumansMaleMiddle AgedAntitubercular AgentsBCG VaccineAcromioclavicular jointBCG therapyBladder cancerCalmette-GuerinMycobacterium bovisOsteoarticular infection

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.